BioMarin Pharmaceutical achieved robust revenue growth in 2025 driven by expanded product sales and strategic acquisition of Inozyme Pharma, yet its operating income and net income declined due to a costly strategic withdrawal of ROCTAVIAN. The company strengthens its pipeline breadth with the pending Amicus Therapeutics acquisition but faces regulatory, pricing, and manufacturing challenges inherent to orphan drug markets. Ongoing financing activities underpin capital deployment for acquisition-driven growth, while operational cash flow generation remains healthy. Investors should monitor execution on pipeline expansion beyond VOXZOGO, regulatory developments in drug exclusivity periods, and integration risks tied to recent M&A.